Safety and Efficacy Results of a Phase I, Open-Label Study of Concurrent and Delayed Nivolumab in Combination With nab-Paclitaxel and Carboplatin in Advanced Non-small Cell Lung Cancer

Safety and Efficacy Results of a Phase I, Open-Label Study of Concurrent and Delayed Nivolumab in Combination With nab-Paclitaxel and Carboplatin in Advanced Non-small Cell Lung Cancer

Introduction: Multicenter, phase I study of concurrent and delayed nivolumab plus nab-paclitaxel/carboplatin in advanced non-small cell lung cancer (NSCLC).Methods: Chemotherapy-naive patients with advanced NSCLC (ineligible for potentially curative radiation or surgery) received nab-paclitaxel 100...

Full description

Bibliographic Details
Main Authors: Jonathan W. Goldman, David M. Waterhouse, Ben George, Peter J. O'Dwyer, Rafia Bhore, Sibabrata Banerjee, Larry Lyons, Chrystal U. Louis, Teng Jin Ong, Karen Kelly
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-11-01
Series:Frontiers in Oncology
Subjects:
non-small cell lung cancer
nab-paclitaxel
carboplatin
nivolumab
treatment beyond progression
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2019.01256/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2019.01256/full

Similar Items